bocunebart

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
bocunebart

GtoPdb Ligand ID: 14313

Compound class: Antibody

Comment: Bocunebart (Lu AG09222 from Lundbeck; formerly ALD1910) is a humanized monoclonal antibody that targets both isoforms of PACAP (PACAP-27 and PACAP-38) [1-2]. It is designed to disrupt PACAP signaling via its receptors as a mechanism to reduce migraine episodes [2-3]. The PACAP epitope engaged by Lu AG09222 is nonlinear, with interactions at amino acids in positions 19, 22, 23, and/or 27 required for potent binding.

References
1. Loomis MC, Garcia-Martinez LF, Dutzar BH, Allison DS, Hendrix KL, Ojala EW, Fan P, Smith JTL, Latham JA, Karasek C et al.. (2021) Humanized anti-PACAP antibodies and uses thereof. Patent number: US10913783B2. Assignee: H Lundbeck AS. Priority date: 14/04/2017. Publication date: 09/02/2021.
2. Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V et al.. (2019) Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide. J Pharmacol Exp Ther, 369 (1): 26-36. [PMID:30643015]
3. Rasmussen NB, Deligianni C, Christensen CE, Karlsson WK, Al-Khazali HM, Van de Casteele T, Granhall C, Amin FM, Ashina M. (2023) The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J Headache Pain, 24 (1): 60. [PMID:37231350]

References

1. Loomis MC, Garcia-Martinez LF, Dutzar BH, Allison DS, Hendrix KL, Ojala EW, Fan P, Smith JTL, Latham JA, Karasek C et al.. (2021)
Humanized anti-PACAP antibodies and uses thereof.
Patent number: US10913783B2. Assignee: H Lundbeck AS. Priority date: 14/04/2017. Publication date: 09/02/2021.

2. Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V et al.. (2019)
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide.
J Pharmacol Exp Ther, 369 (1): 26-36. [PMID:30643015]

3. Rasmussen NB, Deligianni C, Christensen CE, Karlsson WK, Al-Khazali HM, Van de Casteele T, Granhall C, Amin FM, Ashina M. (2023)
The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.
J Headache Pain, 24 (1): 60. [PMID:37231350]